Invivyd, Inc. (NASDAQ:IVVD) Given Average Rating of “Hold” by Analysts

Shares of Invivyd, Inc. (NASDAQ:IVVD) have been given a consensus recommendation of “Hold” by the six brokerages that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $8.00.

Several research analysts have recently weighed in on the stock. BTIG Research reaffirmed a “buy” rating and issued a $10.00 price target on shares of Invivyd in a report on Monday. HC Wainwright restated a “buy” rating on shares of Invivyd in a research report on Thursday, May 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Invivyd in a research report on Wednesday, April 29th. Finally, Wall Street Zen lowered Invivyd from a “hold” rating to a “strong sell” rating in a research report on Saturday.

Invivyd Stock Performance

Invivyd stock opened at $1.04 on Wednesday. The stock has a market cap of $306.39 million, a P/E ratio of -3.35 and a beta of 0.71. Invivyd has a fifty-two week low of $0.48 and a fifty-two week high of $3.07. The firm’s fifty day moving average price is $1.49 and its 200-day moving average price is $1.89.

Invivyd (NASDAQ:IVVD) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.05). The firm had revenue of $13.74 million during the quarter, compared to the consensus estimate of $18.04 million. Invivyd had a negative return on equity of 53.48% and a negative net margin of 138.90%. Sell-side analysts predict that Invivyd will post -0.43 earnings per share for the current year.

Hedge Funds Weigh In On Invivyd

A number of large investors have recently modified their holdings of the company. Perceptive Advisors LLC purchased a new position in shares of Invivyd during the fourth quarter worth approximately $53,809,000. BVF Inc. IL bought a new stake in shares of Invivyd in the 4th quarter worth approximately $48,227,000. RA Capital Management L.P. bought a new stake in shares of Invivyd in the 3rd quarter worth approximately $18,831,000. ADAR1 Capital Management LLC bought a new stake in shares of Invivyd in the 3rd quarter worth approximately $8,108,000. Finally, Janus Henderson Group PLC lifted its holdings in shares of Invivyd by 28.2% in the 4th quarter. Janus Henderson Group PLC now owns 32,543,142 shares of the company’s stock worth $80,870,000 after acquiring an additional 7,160,065 shares during the last quarter. 70.36% of the stock is owned by hedge funds and other institutional investors.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.